

Total: 144 NSCLC patients tested for SIP

**ICI discovery cohort**

37 patients evaluable for SIP

4 patients were not evaluable for disease clinical benefit (not enough follow up)

37 patients evaluable for objective response and survival and SIP

**ICI validation cohort**

46 patients evaluable for SIP

3 patients died without radiological evaluation upon ICI

43 patients were evaluable for response by RECIST v1.1

16 patients had not available pre-ICI radiological evaluations or no measurable disease

27 patients were evaluable for tumor growth rate (TGR) variation before and upon ICI

**PCT control cohort**

61 patients evaluable for SIP, responses and survival

22 patients evaluable also for activation/T-regulatory panel

21 patients evaluable also for dynamic evolution of SIP after ICI start

40 patients evaluable also for polarization panel

22 patients evaluable also for cytokine production

13 patients evaluable also for proliferation assay